Sweet & low: new treatment for diabetes that may reduce blood pressure.

about

Sweet & low: new treatment for diabetes that may reduce blood pressure.

Item

http://www.wikidata.org/entity/Q38101387

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Sweet & low: new treatment for diabetes that may reduce blood pressure.

@en

type

Item

label

Sweet & low: new treatment for diabetes that may reduce blood pressure.

@en

prefLabel

Sweet & low: new treatment for diabetes that may reduce blood pressure.

@en

P1476

Sweet & low: new treatment for diabetes that may reduce blood pressure.

@en

P2093

Debbie L Cohen

http://www.w3.org/2001/XMLSchema#string

Raymond R Townsend

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.

The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats.

Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat.

Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.

P304

305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCH.12092

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236327343

http://www.w3.org/2001/XMLSchema#string

P698

23614842

http://www.w3.org/2001/XMLSchema#string